Maybe you have more experience with patients at this specific dose range than I do. I remain skeptical this could be double blind, but do have less certainty than I originally started with.

I do agree with your skepticity. A better study design could use midazolam as placebo. And I think a good idea would be to ask the participants amd their physicians, which one do they think they received. That would give some idea about how well the double blind design did. Also, many commenters seem to disagree with me, which I also have to be take into consideration. My n is very low as my hospital has just started ketamine treatments.